Synergy between Toxoplasma gondii type I Δ GRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors by Zhu, Yu Chao et al.
1Zhu Y- C, et al. J Immunother Cancer 2021;9:e002970. doi:10.1136/jitc-2021-002970
Open access 
Synergy between Toxoplasma gondii 
type I ΔGRA17 immunotherapy and PD- 
L1 checkpoint inhibition triggers the 
regression of targeted and distal tumors
Yu- Chao Zhu   ,1,2 Hany M Elsheikha,3 Jian- Hua Wang,1,2 Shuai Fang,1,2 
Jun- Jun He,4 Xing- Quan Zhu,5,6 Jia Chen1,2
To cite: Zhu Y- C, Elsheikha HM, 
Wang J- H, et al.  Synergy 
between Toxoplasma gondii 
type I ΔGRA17 immunotherapy 
and PD- L1 checkpoint inhibition 
triggers the regression of 
targeted and distal tumors. 
Journal for ImmunoTherapy 
of Cancer 2021;9:e002970. 
doi:10.1136/jitc-2021-002970
 ► Additional supplemental 
material is published online only. 
To view, please visit the journal 
online (http:// dx. doi. org/ 10. 
1136/ jitc- 2021- 002970).
Accepted 01 October 2021
For numbered affiliations see 
end of article.
Correspondence to
Professor Xing- Quan Zhu;  
 xingquanzhu1@ hotmail. com
Associate Professor Jia Chen;  
 chenjia@ nbu. edu. cn
Associate Professor Hany M 
Elsheikha;  
 hany. elsheikha@ nottingham. 
ac. uk
Original research
© Author(s) (or their 
employer(s)) 2021. Re- use 
permitted under CC BY- NC. No 
commercial re- use. See rights 
and permissions. Published by 
BMJ.
ABSTRACT
Background In this study, we hypothesize that the ability 
of the protozoan Toxoplasma gondii to modulate immune 
response within the tumor might improve the therapeutic 
effect of immune checkpoint blockade. We examined the 
synergetic therapeutic activity of attenuated T. gondii RH 
ΔGRA17 strain and programmed death ligand- 1 (PD- L1) 
treatment on both targeted and distal tumors in mice.
Methods The effects of administration of T. gondii RH 
ΔGRA17 strain on the tumor volume and survival rate 
of mice bearing flank B16- F10, MC38, or LLC tumors 
were studied. We characterized the effects of ΔGRA17 
on tumor biomarkers’ expression, PD- L1 expression, 
immune cells infiltrating the tumors, and expression of 
immune- related genes by using immunohistochemistry, 
immunofluorescence, flow cytometry, NanoString platform, 
and real- time quantitative PCR, respectively. The role 
of immune cells in the efficacy of ΔGRA17 plus PD- L1 
blockade therapy was determined via depletion of immune 
cell subtypes.
Results Treatment with T. gondii ΔGRA17 tachyzoites 
and anti- PD- L1 therapy significantly extended the survival 
of mice and suppressed tumor growth in preclinical 
mouse models of melanoma, Lewis lung carcinoma, and 
colon adenocarcinoma. Attenuation of the tumor growth 
was detected in the injected and distant tumors, which 
was associated with upregulation of innate and adaptive 
immune pathways. Complete regression of tumors was 
underpinned by late interferon- gamma- producing CD8+ 
cytotoxic T cells.
Conclusion The results from these models indicate that 
intratumoral injection of ΔGRA17 induced a systemic 
effect, improved mouse immune response, and sensitized 
immunologically ‘cold’ tumors and rendered them sensitive 
to immune checkpoint blockade therapy.
BACKGROUND
Immunotherapy has been a useful tool 
in the clinical management of cancer in 
addition to surgery, radiation, and chemo-
therapy.1 In particular, immune checkpoint 
blockade (ICB) therapies have been used 
in the treatment of multiple cancers (eg, 
hepatocarcinomas, gastric cancers, head and 
neck cancers, metastatic colorectal cancer 
and skin melanomas, squamous carcinoma 
of the lung, renal cell carcinoma, urothe-
lial carcinoma, mismatch repair- deficient 
tumors, Hodgkin’s lymphoma and Merkel 
cell carcinomas) via antibodies inhibiting 
programmed death- 1 (PD- 1), programmed 
death ligand- 1 (PD- L1), and cytotoxic 
T- lymphocyte- associated protein 4 (CTLA- 4) 
immune checkpoints.2 3 Unfortunately, the 
therapeutic effectiveness of immune check-
point inhibitors can be compromised by 
factors related to tumor microenvironment 
and tumor genome, leading to ‘cold’ tumors 
that are tolerant to ICB therapy in some 
patients. These factors include, for example, 
PD- L1 expression level,4 5 tumor- infiltrating 
lymphocytes (TILs),6 mutational load and 
generation of neoantigens,7 increased infil-
tration of myeloid- derived suppressor cells 
(MDSCs),8–13 lack of major histocompati-
bility complex I (MHC- I) expression,14 and 
mutations in Janus kinase 1/2.15 These chal-
lenges increased the interest in the explora-
tion of more innovative immuno- therapeutic 
approaches that bolster the antitumor immu-
nity by switching non- infiltrated ‘cold’ tumors 
into more immunogenic, immune- infiltrated, 
‘hot’ tumors.
Pathogens have been exploited as potential 
cancer immunotherapeutic agents, including 
tumor- targeting bacteria and oncolytic viruses 
(OVs),16–18 and some protozoan parasites, 
such as Trypanosoma cruzi and Plasmodium 
sp, can thwart the development of tumors 
in animal models.19 20 The OVs have been 
promoted as a therapeutic platform to deploy 
ICB or used in combination with ICB, due to 
their ability to augment the responses in some 
patients and tumor types that respond poorly 
to ICB.17 Despite the clinical utility of these 
OVs, particularly in combination with other 
chemotherapeutic and immunotherapeutic 
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agents,21 the antitumor efficacy of OV monotherapy 
can be compromised in patients who are infected and/
or harbor pre- existing neutralizing antiviral antibodies, 
activated complement or cytokines, which may atten-
uate the OV’s activity, and even clear these viruses.22 23 
To overcome these limitations, exploring the potential of 
other pathogens as cancer immunotherapeutic agents is 
warranted.
The intracellular protist Toxoplasma gondii can invade 
nearly all nucleated cells and infect many warm- blooded 
animals.24 T. gondii is also widely prevalent in human 
population worldwide.25 The efficacy of fully attenuated, 
avirulent, T. gondii uracil auxotroph strains (ΔCPS and 
ΔOMPDCΔUP) as vaccine candidates has been shown.26–30 
These strains can be grown normally in vitro with uracil 
supplementation; however, inside the mammalian hosts, 
these strains cannot replicate and are eliminated by the 
host immune system within ~5 days.3031 In previous immu-
notherapy studies of established melanomas, and ovarian 
and pancreatic tumors, ΔCPS and ΔOMPDCΔUP strains 
increased the immunogenicity of the tumor microenvi-
ronment, reversed tumor- associated immune suppres-
sion, increased antigen processing, presentation, priming 
and activation of tumor antigen- specific CD8+ T cells, and 
completely regressed tumors or significantly extended 
mouse survival.30 32–38 The immunotherapeutic effect 
induced by T. gondii uracil auxotroph requires live para-
sites,30 38 active invasion,30 and secretion of parasite- derived 
rhoptry and dense granule (GRA) effector proteins into 
the host cells.30 A previous study showed that secretion 
of GRA24 into host cells by attenuated T. gondii strongly 
induces interleukin 12 (IL- 12)- dependent CD8+ T cell 
activation and elicits protective immunity independent 
of MyD88 signaling and murine- specific toll- like recep-
tors TLR11 and TLR12, which are absent in humans.39 
Significantly, the efficacy of attenuated T. gondii immu-
notherapy was not diminished by either pre- existing 
chronic T. gondii infection26 or by pre- existing immunity 
to T. gondii,30 indicating that attenuated T. gondii therapy 
could be advantageous in comparison with OVs or other 
pathogen- based immunotherapies which are compro-
mised by existing immune responses to the pathogen. 
These findings suggest that T. gondii can offer an effec-
tive antitumor therapeutic platform for cancer immu-
notherapy. However, the precise mechanisms used by 
attenuated T. gondii to transform ‘cold’ tumors into ‘hot’ 
tumors and whether tumor immunotherapy with attenu-
ated T. gondii could sensitize the tumors to treatment with 
ICB are unknown.
The advent of the gene editing clustered regularly 
interspaced short palindromic repeats (CRISPR)/Cas9 
(CRISPR- Cas9) system has facilitated the genetic manipu-
lation of T. gondii.40 Some attenuated T. gondii strains have 
been constructed using CRISPR- Cas9 such as ΔGRA17, 
which induces a strong adaptive immune response, asso-
ciated with CD8+ T cell maturation and expansion, and 
increased expression of IL- 12 and interferon- gamma 
(IFN-γ).40 41 These immune responses can also potentiate 
an effective antitumor immunity, indicating that ΔGRA17 
can be used to induce antitumor immunity to thwart the 
growth of tumors.
In this study, we show that the combination therapy 
using intratumoral administration of the avirulent 
ΔGRA17 mutant T. gondii strain and anti- PD- L1 therapy 
significantly arrests tumor growth compared with each 
treatment alone. We found that intratumoral injection of 
ΔGRA17 strain increased lymphocyte infiltration in local 
(parasite- injected) and distant (non- parasite- injected) 
tumors. Our data also revealed that intratumoral injec-
tion of ΔGRA17 sensitized the microenvironment of not 
only ΔGRA17- injected tumors but also the contralateral 
(distant) tumors to systemic PD- L1 blockade treatment, 
leading to reduction in tumor size and improved survival 
in most treated mice.
METHODS
Sources of antibodies
The following antibodies were purchased from BD 
Biosciences (Waltham, Massachusetts, USA): anti- CD45 
(AF700, clone: 30- F11), anti- CD3 (BV421, clone: 145- 2 
C11), anti- CD4 (BV510, clone: RM4- 5), anti- CD8 (PE, 
clone: 53- 6.7), anti- NK1.1 (PE- CY7, clone: PK136), anti- 
CD11b (BV605, clone: M1/70), anti- CD11c (APC, clone: 
HL3), anti- PD- 1 (BV650, clone: J43), anti- PD- L1 (BV650, 
clone: MIH5), anti- FoxP3 (AF647, clone: MF23), anti- 
IFN-γ (AF647, clone: XMG1.2), anti- Ki- 67 (AF488, clone: 
B56), anti- granzyme B (eFluor 660, clone: NGZB), anti- 
CD80 (BV421, clone: 16- 10 A1), anti- CD86 (BV450, GL1), 
and anti- TNF-α (AF488, clone: MP6- XT22). Additionally, 
anti- PD- 1 (clone: RMP1- 14), anti- PD- L1 (clone: 10F.9G2), 
anti- CD4 (clone: GK1.5), anti- CD8 (clone:2.43), and anti- 
NK1.1 (clone: PK136) were purchased from BioXcell 
(Lebanon, USA).
Cell lines and culture conditions
The cell lines were purchased from American Type 
Culture Collection (ATCC, Manassas, Virginia, USA), 
including murine B16- F10 melanoma cells (CRL- 6475), 
murine Lewis lung carcinoma LLC (CRL- 1642), murine 
colon adenocarcinoma cells MC38 (Kerafast ENH204- FP), 
and human foreskin fibroblasts (HFFs) (SCRC- 1041). 
Murine melanoma B16- F10 labeled with luciferase (B16- 
F10- Luc) was generated as described previously.42 These 
cell lines were routinely cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% heat- 
inactivated fetal bovine serum (HI- FBS; Gibco, New York, 
USA) and 1% penicillin- streptomycin- glutamine 100x 
(Thermo, Waltham, Massachusetts, USA). HFFs were 
used to culture T. gondii ΔGRA17 tachyzoites. Lympho-
cytes were grown in RPMI 1640 medium containing 
10% of HI- FBS, 10 mM HEPES, 1 mM sodium pyru-
vate, 0.05 mM β-mercaptoethanol, 1% penicillin–strep-
tomycin–glutamine, and 1× minimal essential medium 
non- essential amino acids. Lymphocytes were used for 
flow cytometry analysis of tumor- infiltrating T cells and 
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the immune status of the injected and uninjected tumors. 
Cultures of all above- mentioned cell lines and T. gondii 
were maintained in a humidified atmosphere at 37°C in 
5% CO2.
Mice
Six to 8 week- old, female C57BL/6 mice and NOD/SCID/
IL- 2R g- chain knockout mice (NSG) were purchased from 
Zhejiang Laboratory Animal Center, Hangzhou, China. 
All mice were maintained on a standard commercial diet 
and sterile water ad libitum throughout the experiments. 
Mice were housed under specific- pathogen- free condi-
tions and a 12 hour/12 hour light–dark cycle. Mice were 
randomly assigned to experimental groups. The study 
protocols were reviewed and approved by the Research 
Ethics Committee of Ningbo University (Permit No. SYXK 
(ZHE) 2019- 0005). Mice were observed two times per 
day and were euthanized once they have reached their 
humane endpoint, including 20% loss of body weight 
from tumor induction, body condition score ≤2, or when 
the tumor size reaches ~1.5 cm.
Construction of T. gondii RH ΔGRA17 mutant strain
Type I T. gondii RH ΔGRA17 strain was constructed using 
CRISPR- Cas9 system as previously described.41 Deletion 
of GRA17 gene in the virulent RH strain diminishes the 
parasite’s ability to proliferate in vitro and partly attenu-
ates its virulence in mice.41 Tachyzoites of ΔGRA17 strain 
were stored frozen at −80°C until analysis. Prior to admin-
istration of ΔGRA17, tachyzoites were purified by filtration 
using a 3.0 µm filter (Nuclepore; Sterlitech, Kent, Wash-
ington, USA) and washed with DMEM culture medium. 
The viability and number of ΔGRA17 tachyzoites were 
determined using trypan blue exclusion assay and cell 
counting with a hemocytometer, respectively.
Optimal dosing of T. gondii ΔGRA17
We performed a titration experiment to determine the 
optimal dose of tachyzoites for examining the therapeutic 
efficacy of intratumoral administration of ΔGRA17 strain. 
Briefly, mice bearing B16- F10 tumors were intratumorally 
injected with phosphate buffered saline (PBS) or serial 
doses of ΔGRA17 tachyzoites (5×103, 1×104, 5×104, or 
1×105) at days 9, 11, and 13 after subcutaneous implanta-
tion of B16- F10 cells in the right flank of mice. A digital 
caliper was used to determine the volume of the subcuta-
neous tumors. The tumor volumes were calculated using 
the formula (width2 ×length)/2.
Efficacy of T. gondii ΔGRA17 against B16-F10 melanoma
We established a unilateral B16- F10 melanoma mouse 
model. Briefly, 1×106 to 3×106 B16- F10 cells were subcu-
taneously inoculated into the right flank of mice. When 
the tumor’s size has reached ~0.5 cm (at ~9 days), 100 
µL of PBS or 5×104 ΔGRA17 tachyzoites were intratumor-
ally injected on days 9, 11, and 13. We then determined 
the antitumor activity of ΔGRA17 treatment on the estab-
lished unilateral B16- F10 melanoma by analyzing the 
tumor volume using a digital caliper, starting from day 
9 and every other day until the end of the experiment 
(ie, 19 days after B16- F10 cell implantation). The tumors 
were dissected out after euthanasia of the mice and the 
tumor’s size was compared between ΔGRA17- treated and 
PBS- treated (control) mice. The body weight of ΔGRA17- 
treated and control mice was monitored two times per 
day up to 30 days.
The expression of mouse melanoma markers, CD63, 
S100β, and Ki67,43 was studied using immunohisto-
chemistry analysis. Briefly, following deparaffinization 
and rehydration of the paraffin- embedded tumor tissue 
sections, the antigen was retrieved with high temperature 
in sodium citrate solution 0.01 M, pH 6.0. Then, histo-
logical sections were incubated with diaminobenzidine 
and counterstained with hematoxylin (Solarbio, Beijing, 
China), followed by incubation with anti- CD63, anti- 
S100β, and anti- Ki67 and antibodies (Servicebio, Wuhan, 
China), and secondary antibodies (Servicebio, Wuhan, 
China). Images were acquired using a microscope with 
×200 magnification (Olympus, Tokyo, Japan).
Immunohistochemical (IHC) staining of treated and 
untreated tumor tissue was scored by two independent 
pathologists blinded to the mouse data according to the 
semiquantitative Immunoreactivity Score (IRS). Cate-
gory A documented the percentage of stained area with 
immunoreactive cells as 0 (0%–5%), 1 (6%–25%), 2 
(26%–50%), 3 (51%–75%), and 4 (76%–100%). Cate-
gory B documented the intensity of immunostaining as 0 
(negative), 1 (weak), 2 (moderate), and 3 (strong). Multi-
plication of category A and B resulted in an IRS ranging 
from 0 to 12.
The survival of ΔGRA17- inoculated and PBS- inoculated 
(control) mice was monitored for up to 30 days. Mice that 
remained tumor- free after 30 days from B16- F10 induc-
tion were rechallenged with B16- F10 cells in the opposite 
(left) flank. These mice were monitored for additional 60 
days (ie, a total of 90 days after tumor implantation) for 
the development of the reimplanted tumors.
Analysis of key parameters of the biologic feasibility of 
ΔGRA17
To test the therapeutic efficacy of ΔGRA17 injected into 
extratumoral sites, we injected mice with 100 µL of PBS 
or 5×104 ΔGRA17 intratumorally, intraperitoneally, or 
intravenously. The tumor volume in mice inoculated by 
each of these three different inoculation routes was deter-
mined up to 19 days and mouse survival was determined 
up to 30 days.
To determine whether latent toxoplasmosis interferes 
with treatment efficacy, we tested the efficacy of ΔGRA17 
against B16- F10 melanoma in mice chronically infected 
via intragastric administration with 10 cysts of T. gondii 
(Type II) PRU strain. The tumor volume was determined 
up to 17 days and mouse survival was determined up to 
30 days.
We investigated whether live ΔGRA17 tachyzoites are 
necessary to achieve the required antitumor efficacy or 
ΔGRA17- derived constituents are sufficient to elicit an 
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adequate immune response via recognition of the para-
site’s molecular patterns. Briefly, tachyzoites obtained 
from viable ΔGRA17 strain or inactivated ΔGRA17 strain, 
prepared by heating to 60℃ for 3 min, were inoculated 
into B16- F10 melanoma- bearing mice as described above. 
The tumor volume in mice inoculated by viable ΔGRA17 
tachyzoites, inactivated ΔGRA17 tachyzoites, or PBS was 
determined up to 19 days, and mouse survival was deter-
mined up to 30 days.
We further used immunocompromised NSG mice 
bearing B16- F10 tumors to determine whether an active 
immune response is necessary for ΔGRA17- mediated 
clearance of pre- existing B16- F10 tumors. The tumor 
volume in NSG mice inoculated by ΔGRA17 tachyzoites 
or PBS was determined up to 16 days, and mouse survival 
was determined up to 20 days.
Tumor-infiltrating T cells (TILs) after administration of 
ΔGRA17
The levels of expression of key proinflammatory cyto-
kines IFN-γ (70- EK280HS), interleukin (IL)−12p40 (70- 
EK2183), and IL- 12p70 (70- EK212HS) in the tumor 
tissue of ΔGRA17- inoculated mice 24 hours after the 
second treatment (ie, on day 12) were determined using 
ELISA kits as per the manufacturer’s instructions (Multi-
sciences, Hangzhou, China). We also analyzed intratu-
moral immune cell infiltration by using flow cytometry. 
Briefly, tumors were dissected out of the mouse tissue 
and digested with 2% FBS, collagenase type I (Clone: 
SCR103, Sigma), and DNase I (Clone: H6254, Sigma) 
in RPMI 1640 medium for 1 hour at 37°C. The tumor 
tissues were homogenized and filtered through a 70 µm 
nylon strainer to obtain single cell suspensions. The levels 
of immune cells expressing CD45+, CD3+, CD4+, CD8+, 
NK1.1, CD11b+, CD11c+, IFN-γ, TNF-α, Ki- 67, and gran-
zyme B were analyzed using Beckman CytoFLEX S and 
FlowJo software (Tree Star, Ashland, Oregon, USA).
Mouse (IFN-γ enzyme- linked immune absorbent 
spot (ELISPOT) assay was used to monitor IFN-γ secre-
tion by tumor- infiltrating T cells as described previ-
ously.26 Briefly, CD8+ T cells were isolated from spleen 
or draining inguinal lymph nodes and purified using 
anti- CD8 MACS magnetic beads (Miltenyi Biotec, 
Bergisch Gladbach, Germany). CD8+ T cells were 
cocultured at 10:1 ratio with cell targets (irradiated 
EL- 4 thymoma cell) for 48 hours in coated and blocked 
ELISpot plates. Cell targets were previously pulsed 
overnight with 1 mg/mL MHC- I–restricted peptide 
epitopes TRP- 2 (melanoma Ag), ovalbumin (OVA), or 
heat- killed T. gondii ΔGRA17 Ag. Control samples were 
pulsed with culture media. IFN-γ–expressing T cells 
were detected and analyzed according to the manufac-
turer’s protocol (BD Bioscience).
We examined whether treatment efficacy could be 
extended to other tumor types via intratumoral admin-
istration of ΔGRA17 in mouse MC38 colon carcinoma 
and LLC lung carcinoma models. Briefly, a similar 
treatment schedule was followed as described above, 
except that MC38 or LLC tumor cells, instead of B16- 
F10 tumor cells, were injected in the right flank of 
mice. MC38 and LLC tumor volume was determined. 
We also studied the intratumoral immune infiltrates 
in LLC or MC38 tumor tissues. We determined the 
percentages of CD45+ immune cells, CD3+ T cells, 
CD4+ T cells, CD8+ T cells, natural killer (NK) cells, 
natural killer T (NKT) cells, macrophages and DCs in 
PBS- treated or ΔGRA17- treated LLC tumor cells and 
PBS- treated or ΔGRA17- treated MC38 tumor cells.
Systemic effects of ΔGRA17 on distant tumors
We investigated whether ΔGRA17 treatment has a systemic 
immune- enhancing effect on non- injected (distant) 
tumors. To establish a bilateral tumor model, 1×106 to 
3×106 of B16- F10, LLC or MC38 cells were subcutane-
ously inoculated into the right flank of mice. Three days 
later, 5×105 to 8×105 cells of each cell line were subcu-
taneously inoculated into the left flank. Then, 5×104 
ΔGRA17 tachyzoites were inoculated inside the right flak 
tumor as described above. We determined the volume of 
the inoculated and non- inoculated (distant) tumors over 
29–31 days and monitored the overall mouse survival in 
the bilateral B16- F10, LLC, or MC38 tumor models over 
40–50 days.
To detect the tumorigenesis of mouse melanoma, B16- 
F10- Luc cells were used to establish B16- F10- Luc tumors, 
and the tumor size was monitored by bioluminescence 
imaging using PerkinElmer IVIS Lumina XRMS instru-
ment (PerkinElmer, Waltham, USA). Immediately before 
the in vivo imaging, mice received intraperitoneally 
200 µL of VivoGlo fluorescein (15 mg/mL) (Promega, 
Madison, USA). Additionally, IHC staining and IRS anal-
ysis of mouse tumor tissues were performed as described 
above to determine the expression of CD63, S100β, and 
Ki67 in melanoma tissue. Furthermore, systemic thera-
peutic efficacy of ΔGRA17 was determined by comparing 
the volume of the injected and distant tumor (ie, MC38 
colon carcinoma and the LLC lung carcinoma) and by 
monitoring the survival of mice.
Analysis of the immune status of the injected and distant 
tumors
We examined whether intratumoral administration of 
ΔGRA17 changes the immune status of non- injected (distant) 
tumors. A treatment schedule was followed as described in 
figure 1A, and B16- F10 tumors were harvested 24 hours after 
the second treatment (ie, on day 12). Dissected tumors were 
digested for preparation of single- cell suspensions followed 
by antibody staining for CD45+, CD3+, CD4+, CD8+, NK1.1, 
CD11b+, CD11c+, IFN-γ, TNF-α, Ki67, and granzyme B. 
Cytometry analysis and IFN-γ ELISPOT assay were performed 
as described above. The numbers of infiltrating immune cells 
in treated tumors and distant, untreated, tumors were deter-
mined and compared.
To determine whether the regression of distant 
tumors was related to the immune responses evoked by 
TILs or to the systemic dissemination of ΔGRA17, we 
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analyzed T. gondii- specific B1 gene expression of ΔGRA17 
tachyzoites using quantitative PCR (qPCR). Briefly, tumor 
cells were injected into both flanks of wild type (WT) mice 
and NSG mice. On day 9, the right flank was injected with 
5×104 ΔGRA17 tachyzoites, and 5 days later (ie, on day 14), 
the injected and the distal tumors were harvested from 
WT and NSG mice. Tumors were homogenized using the 
gentle MACS Dissociator (Miltenyi Biotec, Bergisch Blad-
bach, Germany) and genomic DNA was isolated using 
a DNA extraction Kit (TIANGEN, Beijing, China). The 
isolated DNA was used as a template to amplify T. gondii 
B1 gene. qPCR was performed using a SYBR Premix Ex 
Taq II (Takara, Tokoyo, Japan) on a Mx3005P real- time 
PCR System (Stratagene, Waltham, Massachusetts, USA) 
as described previously.44
We established a standard curve to quantify the number 
of ΔGRA17 tachyzoites from the Ct values obtained from 
qPCR analysis of tumor tissues. Briefly, DNA was isolated 
from a 10- fold dilution series of ΔGRA17 tachyzoites (106, 
105, 104, 103). qPCR was carried out as described above. 
This experiment was repeated three times, and mean Ct 
values were used to generate a standard curve (R2=0.99, 
E=98%, y=−2.252x+31.02) by plotting the Ct values 
against the logarithm of the numbers of tachyzoites in 
Figure 1 Toxoplasma gondii ΔGRA17 strain significantly reduces the growth of melanoma in mice. (A) Schematic 
representation of the treatment regimen and timeline for mice inoculated with B16- F10 cells in the right flank. Once the B16- F10 
tumor size has reached 5 mm at ~9 day, the tumor was injected with 100 µL of phosphate buffered saline (PBS) (control) or 
5×104 ΔGRA17 tachyzoites and then again at days 11 and 13 after implantation of B16- F10 cells. Using a vernier caliper, the 
tumor size was measured, starting from day 9 and every other day until 19 days after B16- F10 cells’ implantation. When the 
tumor size has reached ~15 mm, mice were humanely euthanized. (B) ΔGRA17 administration significantly reduced the tumor 
size compared with control mice treated with PBS only. (C) The size and location of the tumors detected in mice euthanized 
on day 19. (D) The tumors dissected from mice shown in (C), showing a significant reduction in the tumor size of ΔGRA17- 
injected mice compared with control mice. (E) Immunohistochemical analysis and the corresponding Immunoreactivity Score 
(IRS) of mouse melanoma markers CD63, S100β, and Ki67. (F) Survival curve of B16- F10- bearing mice shows a significant 
improvement in the survival of ΔGRA17- inoculated mice compared with control mice. (G) Tumor- free mice were reinoculated in 
the left flank with 1×106 to 3×106 B16- F10 cells at 30 days and their survival was monitored for 60 days (ie, 90 days after tumor 
implantation). The survival of tumor- bearing mice was presented as Kaplan- Meier plots and tested for significance using log- 
rank tests. Data are mean±SD (n=6 mice/group) of three independent experiments; unpaired Student’s t- test, *p<0.05, **p<0.01, 
***p<0.001, n/s, not significant, compared with the indicated control.
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each dilution. Linear regression analysis was used to fit 
the curve to the data. PCR amplification efficiency (E) 
was calculated from the slope of the standard curve using 
the equation E = [10−1/slope−1].
Profiling immune-related genes in treated and distant tumors 
of ΔGRA17-treated mice
We further examined whether intratumoral adminis-
tration of ΔGRA17 changes the immune status of the 
distant tumors in B16- F10- bearing mice. NanoString 
platform (WuXi AppTec, Shanghai, China) was used to 
study the gene expression of the injected tumors, distant 
tumors, and control mouse groups. Briefly, B16- F10 
tumor- bearing mice were treated with PBS or ΔGRA17 
as described above. Twenty- four hours after the second 
treatment (ie, on day 12), RNA was isolated from the 
dissected tumors and hybridized with the PanCancer 
Mouse Immune Profiling panel and quantified using 
the digital analyzer (nCounter). Data were processed 
and normalized using nSolver Analysis Software and the 
Advanced Analysis module (NanoString Technologies, 
Waltham, Massachusetts, USA). The expression profile of 
immune- related pathways was determined in the injected 
and distant tumors. The ggpubr R package was used to 
construct the volcano plots and pheatmap R package was 
used to perform hierarchical clustering of tissue gene 
expression.
The expression levels of mRNA of genes (H2- K1, 
CD74, H2- Eb1, H2- T23, H2- Aa, Psmb8, CCL3, IL1b, CD80, 
Fas, IL2RA, and JAK3) involved in antigen processing 
and T cell function in the injected and distant tumors 
were determined by quantitative reverse transcriptase 
PCR (qRT- PCR). Briefly, total RNA was isolated from 
B16- F10 tumor tissue using Trizol reagent (Invitrogen, 
Waltham, Massachusetts, USA). DeNovix DS- 11 spectro-
photometer (DeNovix, Waltham, Massachusetts, USA) 
was used to detect the purity and concentration of RNA. 
qRT- PCR analysis was performed using SYBR Premix Ex 
Taq II (Takara, Tokyo, Japan) with a Mx3005P real- time 
PCR System (Stratagene, La Jolla, California, USA). The 
primer sequences are provided in the online supple-
mental material.
Immunofluorescence analysis was also used to quantify 
the level of expression of PD- L1 in injected and distant 
tumors. Briefly, formalin- fixed, paraffin- embedded B16- 
F10 tumor tissue was cut into 6 µm. The sections were 
deparaffinized in xylene and rehydrated in a graded 
series of ethanol. For antigen retrieval, the sections were 
immersed in 10 mM sodium citrate (pH 6.0), heated in 
a water bath at 95°C–99°C for 20 min, and then cooled 
to room temperature. Then, slides containing B16- F10 
tumor tissue were fixed for 10 min at 4°C in 4% para-
formaldehyde in PBS, permeabilized with 0.1% Triton 
X- 100 (Sigma- Aldrich, USA) for 10 min at room tempera-
ture, and blocked for 1 hour in PBS with 1% horse serum 
(Sigma- Aldrich, Saint Louis, USA) overnight at 4°C and 
washed three times for 5 min with PBS. Slides were subse-
quently incubated with primary antibodies: anti- PD- L1 
(1:100; clone: ab213524, Abcam, Cambridge, UK) and 
anti- Firefly- Luciferase (1:100, clone: ab21176, Abcam, 
Cambridge, UK). Alexa Fluor secondary antibody (1:500; 
ab150077, Abcam, Cambridge, UK) was added for 1 
hour at room temperature in the dark. The slides were 
washed three times with PBS and DAPI (Sigma- Aldrich, 
Saint Louis, USA) was added to the first wash to stain 
the nuclei. Images were acquired using a Confocal Zeiss 
LSM880. Intensity analysis was performed using ImageJ 
V.1.51j8 (National Institutes of Health, USA).
To further examine how PD- L1 expression is influ-
enced in B16- F10 cells following ΔGRA17 infection, B16- 
F10 cells cultured in vitro were PBS treated (control) or 
infected with ΔGRA17 tachyzoites and harvested after 24 
hours. The cells were then blocked with a- CD16/32 Ab 
(clone 93, eBioscience; 1:1000) and stained with anti-
bodies against mouse PD- L1. The cell surface expression 
levels of PD- L1 were shown as mean fluorescence inten-
sity (MFI) values.
We examined whether T. gondiiΔGRA17 treatment 
increased expression of CD80 in the tumor microenvi-
ronment. CD45+CD11c+ cells from ΔGRA17- injected and 
distant B16- F10 tumor- bearing mice were analyzed for the 
expression CD80+ using flow cytometry.
Combination therapy using ΔGRA17 and PD-L1 blockade
To examine the efficacy of intratumoral therapy using 
ΔGRA17 and PD- L1 on bilateral (injected and distant) 
melanomas, B16- F10- bearing mice were treated with 
ΔGRA17 on one side in addition to intraperitoneal injec-
tion with or without 250 µg anti- PD- L1 antibody on days 
9, 11, and 13. Control mice included age- matched B16- 
F10- bearing mice treated with PBS. The tumorigenesis or 
regression of mouse B16- F10- Luc cells was determined 
using bioluminescence imaging as described above. The 
tumor volume (up to 30 days) and survival (up to 60 days) 
of mice receiving monotherapy or dual therapy was deter-
mined. Body weight in each mouse group was also deter-
mined. Mice were deemed to be completely cured when 
no tumor was detected by palpation. Mice cured of B16- 
F10 tumors and age- matched tumor- naive (control) mice 
were rechallenged with the same tumors within 25 days. 
The previously cured mice were treated with a combina-
tion therapy (ΔGRA17 and PD- L1 blockade) in the right 
flank on day 60 to determine the long- term persistence 
of antitumor memory, while control mice received no 
treatment.
Role of immune cells in the efficacy of the dual ΔGRA17 plus 
PD-L1 blockade therapy
We determined which cellular subsets underlay the 
observed therapeutic effect of the combined therapy 
and investigated the role of cellular subsets during early 
and late stage of dual therapy. Briefly, mice were injected 
intraperitoneally with 500 µg monoclonal antibodies 
(Ab) to CD8+, CD4+, or NK1.1, either the day before 
tumor implantation (day –1) or on the first day of treat-
ment (day 0), followed by injections of 250 µg every 5 days 
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until mice have reached their humane endpoint. Animals 
that did not receive any depleting Ab for CD4+, CD8+, and 
NK cells were used as controls. The survival of mice was 
monitored two times per day.
Statistical analysis
Statistical analysis was performed using GraphPad Prism 
V.8 (GraphPad Software, California, USA). Two- tailed 
Student’s t- test was used to derive the significance of the 
differences between the two groups. Differences were 
considered significant when p<0.05. We used log- rank tests 
for the Kaplan- Meier survival analysis. The numbers of 
mice used in each experiment are provided in the figure 
legends. Data are presented as mean±SD. All experiments 
were performed in triplicate.
RESULTS
T. gondii ΔGRA17 strain regresses B16-F10 melanoma
The dose- dependent tumor growth regression analysis 
identified 5×104 ΔGRA17 tachyzoites as the optimal dose 
to examine the efficacy of intratumoral administration 
of ΔGRA17 on the tumor growth (online supplemental 
figure S1). We evaluated the antitumor effects of ΔGRA17 
on a unilateral flank B16- F10 tumor model in immuno-
competent mice (figure 1A). In agreement with a previous 
study,26 intratumoral injection of ΔGRA17 resulted in 
growth arrest of the unilateral melanoma and a regres-
sion in the size of parasite- injected tumors (figure 1B, C 
and D) without any impact on the body weight of mice 
(online supplemental figure S2). To characterize the 
tumor growth, mice were killed on day 19 and B16- F10 
melanoma tissue samples were collected, and the level of 
expression of three melanoma markers42 was determined 
using immunohistochemistry. Mice injected with ΔGRA17 
exhibited a lower malignancy as shown by increased expres-
sion of CD63 tetraspanin, and lower metastatic burden 
as indicated by decreased expression of S100β and Ki67 
(figure 1E). We also detected a significant increase in the 
survival of mice bearing B16- F10 melanoma (figure 1F). 
After 30 days, tumor- free mice were rechallenged with 
B16- F10 cells in the left flank. Mice were monitored for 
additional 60 days (ie, 90 days after tumor implantation). 
Approximately 70% of the rechallenged mice rejected 
the reimplanted tumors (figure 1G).
To test the therapeutic potential of ΔGRA17 mono-
therapy injected into non- tumor sites, we infected mice 
with ΔGRA17 intratumorally, intraperitoneally, or intra-
venously. As expected, intravenous and intraperitoneal 
injection of ΔGRA17 did not attenuate the tumor growth, 
nor did it improve the survival of mice with an estab-
lished B16- F10 melanoma (figure 2A,B). This suggests 
that ΔGRA17 tachyzoites must be in the tumor microenvi-
ronment to induce protective immunity against a primary 
tumor.
Latent infection is often accompanied with a pre- 
existing immunity that attenuates oncolytic virus activity 
and reduces treatment efficacy against tumors.16 Latent 
T. gondii infection is widespread worldwide,25 and was 
previously shown to not interfere with T. gondii uracil 
auxotroph immunotherapy of B16F10 tumors.26 There-
fore, we determined if chronic toxoplasmosis interferes 
with the treatment efficacy by testing the efficacy of 
ΔGRA17 against B16- F10 melanoma in mice infected by 
T. gondii PRU strain, which produces a latent infection. 
Chronic infection did not influence the antitumor effi-
cacy induced by ΔGRA17 (figure 2C), indicating that pre- 
existing T. gondii infection is unlikely to interfere with the 
antitumor efficacy of ΔGRA17 treatment.
Previous studies have demonstrated the necessity for 
live pathogens to achieve antitumor efficacy.26 On the 
other hand, T. gondii components can be effective in 
the regression of tumor outgrowth.45 To establish if live 
ΔGRA17 tachyzoites are necessary for antitumor efficacy, 
established tumors were inoculated with viable or heat- 
inactivated ΔGRA17 tachyzoites. Treatment with inacti-
vated ΔGRA17 tachyzoites resulted in a major failure to 
delay tumor growth or to improve survival time in all 
treated mice (figure 2D), demonstrating the need for live 
pathogens to obtain antitumor efficacy.
Antitumor efficacy of intratumorally administrated 
pathogens often depends on an active host immune 
response being induced by their invasion into tumors.16 
To reveal the requirement of an effector immune 
response for ΔGRA17- mediated clearance of pre- existing 
B16- F10 tumors, we examined the therapeutic efficacy of 
ΔGRA17 treatment in NSG mice- bearing B16- F10 tumors. 
No protection was observed in these immunocompro-
mised mice (figure 2E), demonstrating that antitumor 
effect of ΔGRA17 is immune- mediated.
Increased TILs after administration of ΔGRA17
Although in vitro cytotoxicity against tumor cell lines has 
been reported in previous studies,46 an activated immune 
mechanism in the tumor microenvironment is the main 
indicator of antitumor efficacy in in vivo mouse models 
following therapy with T. gondii.37 IL- 12 is required for 
CD8+ T cell- dependent immunity against T. gondii, and 
also IL- 12 and IFN-γ production are indispensable for 
the therapeutic efficacy of non- replicating completely 
attenuated T. gondii CPS strain.34 47 48 In line with previous 
studies, we detected significant increase in the expres-
sion of IL12p40, IL12p70, and IFN-γ in the ΔGRA17- 
inoculated tumors (online supplemental figure S3). 
Therefore, we further analyzed intratumoral inflamma-
tory cell infiltration by flow cytometry. Examination of the 
parasite- injected tumors revealed an increased intratu-
moral infiltration with immune cells expressing leukocyte 
common antigen CD45 (figure 3A). The intratumoral 
immune cell infiltrates were characterized by an increase 
in innate and adaptive immune components, including 
CD3+ T cells, CD4+ T cells, CD8+ T cells, NK cells, NKT 
cells, CD11b+ (macrophages), and CD11b+CD11c+ 
(dendritic cells, DCs) (figure 3A,B). Also, effector T cells 
expressing increased effector, proliferation, and lytic 
markers were detected in the injected tumors, including 
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tumor necrosis factor-α (TNF-α) and IFN-γ, Ki- 67, and 
granzyme B (figure 3C). Additionally, IFN-γ ELISPOT 
showed a significantly increased melanoma Ag (TRP- 2)- 
specific CD8+ T cells after ΔGRA17 treatment (figure 3D). 
These data demonstrated that tumor specific CD8+ T cells 
response was elicited after ΔGRA17 inoculation.
We examined the effect of intratumoral administra-
tion of ΔGRA17 in MC38 colon carcinoma and LLC 
lung carcinoma models to determine if treatment 
efficacy could be extended to other tumor types. As 
with the B16- F10 model, this treatment strategy also 
regressed growth of the injected tumor, which accords 
with intratumoral immune infiltrates in these two 
models (figure 3E, F and G).
Effects on non-injected distant tumors
To test if intratumoral injection with ΔGRA17 is able to 
provoke systemic antitumor activity, we evaluated anti-
tumor activity using a bilateral B16- F10 melanoma model, 
where mice had subcutaneous B16- F10 melanoma inocu-
lated into both flanks (figure 4A). Intratumoral therapy 
with ΔGRA17 delayed growth of the inoculated tumor and 
the distant tumors, in addition to increasing the mouse 
survival (figure 4B). This finding supports the potential 
efficacy of this parasite therapy against distant metastatic 
disease.
Remarkably, luminescence images from mice treated 
with ΔGRA17 showed a reduced value of the lumi-
nescence color in the inoculated and distant tumors 
compared with PBS- injected controls, and even no value 
of the luminescence color was observed in some ΔGRA17- 
injected tumors compared with that in controls, which 
Figure 2 Biological feasibility and characteristics of Toxoplasma gondii ΔGRA17 strain. (A) Changes in the tumor volume of 
mice injected with ΔGRA17 using the three indicated inoculation methods compared with phosphate buffered saline (PBS)- 
treated (control) mice. (B) Survival of B16- F10 tumor- bearing mice injected using the shown three different inoculation methods. 
(C) Tumor volume and survival of B16- F10 tumor- bearing mice treated with PBS or ΔGRA17 tachyzoites after establishment of a 
latent infection by T. gondii PRU strain. (D) Tumor size and survival of mice following inoculation with heat- inactivated ΔGRA17 
tachyzoites. (E) Tumor size and survival of B16- F10 tumors in NOD/SCID/IL- 2gR knockout (KO) mice. The survival of tumor- 
bearing mice was presented as Kaplan- Meier plots and tested for significance using log- rank tests. Data are mean±SD (n=5 
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Figure 3 Toxoplasma gondii ΔGRA17 increases infiltration of tumors with lymphocytes. A treatment schedule shown in 
figure 1A was followed, B16- F10 tumors were harvested 24 hours after the second treatment (ie, on the 12th day), and digested 
for preparation of single- cell suspensions followed by antibody staining for CD45, CD3, CD4, CD8, NK1.1, CD11b, CD11c, 
interferon- gamma (IFN-γ), tumor necrosis factor-α (TNF-α), Ki67, and granzyme B. (A) Representative plots of the percentages 
of CD45+ cells, CD3 T cells, CD4+ T cells, CD8+ T cells, natural killer (NK) cells, macrophages, and dendritic cells (DCs) in 
phosphate buffered saline (PBS)- treated or ΔGRA17- treated tumors. (B) Percentages of CD45+ cells, CD3 T cells, CD4+ T 
cells, CD8+ T cells, NK cells, natural killer T (NKT) cells, macrophages, and DCs in PBS- treated or ΔGRA17- treated tumors. 
(C) Percentages of interferon- gamma (IFN-γ), tumor necrosis factor-α (TNF-α), ki67, and granzyme B in CD8+ T cells. (D) IFN-γ 
ELISPOT showing that tumor Ag TRP- 2- specific CD8+ T cells in spleen are enriched in infiltrated lymphocytes. (E– G) A similar 
treatment schedule was followed as in figure 1A, except that LLC or MC38 tumor cells were used to inject the mice, instead 
of B16- F10 tumor cells. (E) LLC and MC38 tumor volume in mice. (F) Percentages of CD45+ immune cells, CD3 T cells, CD4+ 
T cells, CD8+ T cells, NK cells, NKT cells, macrophages, and DCs in phosphate buffered saline (PBS)- treated or ΔGRA17- 
treated LLC tumors. (G) Percentages of the CD45+ immune cells, CD3 T cells, CD4+ T cells, CD8+ T cells, NK cells, NKT cells, 
macrophages, and DCs in PBS- treated or ΔGRA17- treated MC38 tumors. Data are mean±SD (n=6 mice/group) of three 
independent experiments; Student’s t- test, **p<0.01, ***p<0.001 compared with the indicated control.
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Figure 4 Intratumoral administration of Toxoplasma gondii ΔGRA17 inhibits the growth of non- injected (distant) tumors. 
(A) Schematic of treatment regimen and timeline for mice inoculated with B16- F10, LLC, or MC38 cells. (B) Growth kinetic 
of injected tumors and distant tumors, and the overall animal survival in a bilateral B16- F10 melanoma mouse model. (C) 
Representative luminescence images of mice injected with melanoma B16- F10- Luc cells and treated with ΔGRA17 compared 
with control mice treated with phosphate buffered saline (PBS). (D) Representative photos of injected and distant melanoma 
tumors. (E) The size of the injected and distant melanoma tumors, corresponding to the mice in (D). (F) Immunohistochemical 
staining analysis of melanoma malignancy and the corresponding Immunoreactivity Score (IRS) of CD63, S100β, and Ki- 67 
expression. (G) Tumor size and mouse survival in bilateral LLC tumor model. (H Tumor size and mouse survival in bilateral 
MC38 tumor model. The survival of tumor- bearing mice was monitored by Kaplan- Meier analysis, and statistical analyses were 
performed with log- rank test. Data are shown as mean±SD (n=6 mice/group) of three independent experiments; Student’s t- 
test, *p<0.05, **p<0.01, ***p<0.001, n/s, not significant compared with the indicated control.
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may indicate a tumor free by luminescence image anal-
ysis. However, these injected right- sided tumors with no 
value of the luminescence color could still be observed, 
but appeared as degraded white tissue (figure 4C, D and 
E). Therefore, we characterized the degree of malignancy 
in the bilateral tumors using IHC staining. Our findings 
showed a lower degree of malignancy with increased 
expression of CD63, and lower tumor proliferation and 
metastasis with decreased expression of S100β and Ki67 
in the ΔGRA17- injected tumors (figure 4F). Systemic 
therapeutic efficacy of ΔGRA17 may also extend to other 
tumor types, including MC38 colon carcinoma and the 
LLC lung carcinoma models (figure 4G,H).
Analysis of the uninjected tumors revealed significant 
changes in immune status, which was identical to the infil-
tration pattern of immune cells observed in the injected 
left flank tumors, characterized by increased numbers of 
innate immune cells and adaptive T cells (figure 5A,B). 
Notably, characterization of CD4+ and CD8+ TILs from 
mice receiving the ΔGRA17 therapy demonstrated down-
regulation of Foxp3- expressing CD4+ cells and PD- 1- 
expressing CD8+ cells with a larger percentage of IFN-γ 
and TFN-α-expressing CD8+ cells in local and distal 
tumors (figure 5B,C). These data suggest that ΔGRA17 
therapy can modulate the immunosuppressive tumor 
microenvironment by enhancing the proliferation and 
activation of the tumor- infiltrating cytotoxic T cells, and 
reduction of immunosuppression.
IFN-γ ELISPOT revealed that tumor Ag TRP- 2- specific 
CD8+ T cells are enriched in the infiltrated lymphocytes 
in the injected and distal tumors after ΔGRA17 immuno-
therapy (figure 5D). We investigated whether the regres-
sion of contralateral tumors was directly due to the immune 
responses evoked by TILs or systemic spread of the parasite. 
We used qPCR to establish a standard curve so that Ct values 
of T. gondii- specific B1 gene expression could be used to 
determine the number of ΔGRA17 tachyzoites and the level 
of infection in injected and distant tumors harvested from 
WT and NSG mice. Intratumoral administration of ΔGRA17 
into the right flank tumor resulted in parasite replication 
within the injected tumors of WT and NSG mice. However, 
no tachyzoites were detected in the distant left flank tumor 
of WT mice (online supplemental figure S4). Interestingly, 
tachyzoites were detected in the distant tumors of the NGS 
mice. These findings suggest that T. gondii infection in WT 
mice was largely limited to the injected tumors, and that 
therapeutic efficacy against contralateral tumors was medi-
ated via immune responses induced by TILs following the 
treatment with ΔGRA17 and not due to the systematic distri-
bution of ΔGRA17 parasites.
ΔGRA17 therapy induces immune changes in treated and 
distant tumors
Although intratumoral injection of ΔGRA17 significantly 
reduced the growth of injected tumors, only moderate or 
low therapeutic efficacy was observed in distant tumors. 
This may have been due to insufficient inflammatory effi-
cacy in driving complete tumor rejection in distant tumors. 
Thus, the potential inhibitory mechanisms of this therapy, 
which has been previously characterized by local injection 
with oncolytic virus,49 50 could be involved in dampening 
the immune response in the microenvironment of ΔGRA17- 
injected and distant tumors. To reveal any potential changes 
in immune pathways, NanoString was used to analyze the 
expression level of immune- related genes in injected and 
distant tumors of ΔGRA17- injected mice. We detected an 
increase in the expression in a range of immune check-
point genes, including PD- L1 (figure 6A), a few of these 
are being explored as targets for cancer immunotherapy.51 
A considerable number of immune response- related path-
ways in injected and distant tumors were also changed after 
treatment with ΔGRA17 (figure 6B).
Among these upregulated immune- inhibitory targets, 
we focused on the PD- 1/PD- L1 pathway, given its prom-
ising role in T cell exhaustion during chronic viral infec-
tion by hepatitis B virus (HBV), hepatitis C virus (HCV), 
and HIV, as well as in anticancer therapies targeting these 
checkpoints and OV in combination with systemic PD- 1 
blockade to treat cancer.52 53 Immunofluorescence anal-
ysis showed a significant increase in the expression of 
PD- L1 in tumor cells in the injected and distant tumors 
in response to ΔGRA17 treatment, while non- tumor cells 
did not contribute to PD- L1 expression (figure 6C). To 
further confirm that PD- L1 expression was upregulated in 
B16- F10 cells following ΔGRA17 infection, cultured B16- 
F10 cells were either sham- treated with PBS (control) or 
infected by ΔGRA17, and harvested after 24 hours. Flow 
cytometry revealed that PD- L1 expression in ΔGRA17- 
infected cells was upregulated (online supplemental 
figure S5). These results showed increase in PD- L1 expres-
sion following ΔGRA17 infection both in vivo and in vitro.
Gene expression analysis revealed an increased expres-
sion of genes related to T cell function, immune pathways 
involved in antigen processing, interferon, inflamma-
tion, chemokines, and receptors, in ΔGRA17- injected and 
distant tumors (figure 6D and online supplemental figures 
S6,S7,S8,S9). Using qRT- PCR, we detected a significant 
increase in the expression of mRNA for genes involved 
in antigen processing and increased T cell function 
(figure 6E,F). We detected increased expression level of 
CD80+ in CD45+CD11c+ cells in injected and distant tumor 
tissues compared with that in control (online supplemental 
figure S10), indicating a comparative antigen processing in 
both ΔGRA17- injected and distant tumors. Results demon-
strated a more intense T cell function in ΔGRA17- injected 
tumors than in distant tumors.
ΔGRA17 and PD-L1 blockade synergize to suppress local and 
distant tumors
We hypothesized that intratumoral administration 
of ΔGRA17 induced changes in immune status, with 
enhanced TILs and the elevated PD- L1 expression by 
cancer cells in the ΔGRA17- injected and distant tumors, 
which would sensitize tumors to PD- L1 blockade therapy, 


















12 Zhu Y- C, et al. J Immunother Cancer 2021;9:e002970. doi:10.1136/jitc-2021-002970
Open access 
Figure 5 Intratumoral administration of Toxoplasma gondii ΔGRA17 strain the immune status of non- injected distant tumors. 
The treatment schedule shown in figure 4A was followed, B16- F10 tumors were harvested 24 hours after the second treatment 
(ie, on day 12), and digested for preparation of single- cell suspensions followed by antibody staining for CD45+, CD3+, CD4+, 
CD8+, NK1.1, CD11b+, CD11c+, interferon- gamma (IFN-γ), tumor necrosis factor-α (TNF-α), Ki67, and granzyme B. (A) The 
numbers of infiltrating CD45+ cells, dendritic cells (DCs), natural killer (NK), natural killer T (NKT), CD4+, and CD8+ T cells in 
treated tumors and distant, untreated, tumors. (B) Representative plots of IFN-γ, TNF-α, programmed death- 1 (PD- 1), Ki- 67, and 
granzyme B of tumor- infiltrating CD8+ T cells and FoxP3 of tumor- infiltrating CD4+ T cells in injected tumors and distant tumors. 
(C) Concentrations of IFN-γ, TNF-α, PD- 1, Ki- 67, granzyme B, and regulatory T cells (Tregs). (D) IFN-γ ELISPOT showing tumor 
Ag TRP- 2- specific CD8+ T cells enriched in intratumoral infiltrated lymphocytes. Data are shown as mean±SD (n=6 mice/group) 
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Figure 6 Toxoplasma gondii ΔGRA17 changes immune status inside the tumors. (A) Volcano plots show overall gene 
expression levels of the injected (T2), distant tumors (T1) and control group (C) as determined by using a NanoString platform. 
(B) Heatmap shows the expression profile of immune- related pathways in B16- F10- bearing mice (n=4 mice per group) treated 
with phosphate buffered saline (PBS) or 5×104 ΔGRA17 tachyzoites. Red and blue color indicate high and low expression, 
respectively. (C) Upregulation of programmed death ligand- 1 (PD- L1) in tumor cells in injected tumors and distant tumors as 
revealed by immunofluorescence analysis. (D) Expression profile of antigen processing genes of tumors from B16- F10- bearing 
mice (n=8 mice/group) treated with PBS or ΔGRA17. Red indicates high expression, and blue indicates low expression. (E, 
F) Expression of representative antigen processing- related genes, chemokine genes and T cell response- related genes in the 
injected and distant tumors was determined by quantitative reverse transcriptase PCR. Data are shown as mean±SD of three 
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To analyze the effects of combined ΔGRA17 and PD- L1 
blockade treatment on the bilateral melanoma, ΔGRA17 
treatment was administered with or without anti- PD- L1 
antibody into tumors on one side (figure 7A). Mono-
therapy with ΔGRA17 or anti- PD- L1 antibody showed 
modest efficacy (figure 7B) and induced no or 2/8 
regression in the distant tumors in mice (figure 7C). In 
contrast, a combination of ΔGRA17 and PD- L1 blockade 
induced a much earlier tumor complete regression than 
ΔGRA17 monotherapy (figure 7B,C), prolonged survival 
of mice (figure 7D), did not influence the mouse body 
weight (online supplemental figure S11), and resulted in 
complete regression of bilateral tumors (online supple-
mental figure S12).
We determined the long- term persistence of antitumor 
memory. Mice cured of B16- F10 tumors and control mice 
were rechallenged with B16- F10 tumor cells within 25 
days, then treated with ΔGRA17 and PD- L1 blockade in 
the right flank on day 60, while control mice received no 
treatment. B16- F10 tumors in the previously cured mice 
showed complete regression against rechallenge of the 
same tumors within 25 days, whereas all age- matched 
tumor- naive control mice developed tumors (figure 7E).
Role of immune cells in the efficacy of ΔGRA17 plus PD-L1 
blockade therapy
We determined which cellular subsets underlay the effi-
cacy of the dual therapy and whether specific cellular 
subsets play a role during the early or late stage of the 
therapeutic effect. An immune cell depletion experiment 
was performed to investigate the contribution of the infil-
trated CD4+, CD8+, and NK cells to the therapeutic effi-
cacy of the combined treatment. B16- F10 tumor- bearing 
mice receiving the combination therapy (ΔGRA17 and 
PD- L1 blockade) were injected with depletion Ab at the 
timepoints shown (figure 8A). Depletion of either NK or 
CD8+ cells led to abrogation of the therapeutic effect, in 
both ΔGRA17- injected and distant tumors, with a signif-
icant reduction in survival (figure 8B,C). These results 
showed the essential roles played by NK and CD8+ cells 
in the therapeutic efficacy of the dual therapy. Remark-
ably, NK cells were essential for therapeutic efficacy 
earlier than CD8+ cells, suggesting NK cells may be imme-
diate immune responders to therapeutic treatment with 
ΔGRA17. On the contrary, depletion of CD4+ cells did not 
cause any significant alteration in the treatment outcome.
DISCUSSION
Recent clinical trials using immunotherapy in the treat-
ment of solid tumors, including immune checkpoint- 
targeted therapies, have produced durable therapeutic 
effects against advanced metastatic cancers, such as mela-
noma, metastatic lung, kidney, and bladder carcinoma.55 56 
However, the most common cancers are resistant to anti- 
PD- 1/PD- L1, anti- CTLA- 4, and their combination, and 
are referred to as ‘cold’ tumors. This failure of immuno-
therapy may be attributed to their low or no mutational 
burden and neoantigen load, poor MHC presentation, 
and insufficient T cell infiltrates, and insensitivity to 
ICB.5 57–61 Improvement in the treatment efficacy against 
poorly immunogenic tumors requires new treatment 
interventions that can induce a robust and durable anti-
tumor immune response capable of markedly thwarting 
the tumor progression and prolonging patient survival.
The present study explored whether a combined treat-
ment approach involving attenuated T. gondii ΔGRA17 
strain and anti- PD- L1 therapy would improve the tumor 
immunogenicity and overcome resistance to ICB- based 
therapies. Our results showed that intratumoral admin-
istration of ΔGRA17 tachyzoites not only changed the 
immune status in the tumor microenvironment (leading 
to regression of local and distant tumors in B16- F10 mela-
noma, MC38 colon carcinoma, and LLC lung carcinoma 
mouse models), but also sensitized B16- F10 melanoma 
to ICB, which is refractory to treatment with anti- PD- L1 
immunotherapy.
In clinical trials, the presence of TILs, especially high 
baseline levels of innate and adaptive immune responses in 
tumor, indicates they are potentially responsive to immuno-
therapy.3 62 In our study, to trigger an inflammatory response 
in tumors, we used avirulent T. gondii RH ΔGRA17 strain, 
which is a potent inducer of T cell maturation and expan-
sion as shown by the increased concentrations of IL- 12 and 
IFN-γ41 that also have an effective antitumor immunity.17 37 In 
our studies, we chose a bilateral flank melanoma model and 
poorly immunogenic MC38 colon carcinoma and LLC lung 
carcinoma model, which have been previously recognized 
to be unaffected by concurrent immunity. We found that 
intratumoral inoculation of ΔGRA17 led to an immune infil-
tration, with activation and expansion of DCs, CD4+ T cells, 
CD8+ T cells, NK cells, and NKT cells in injected and distant 
tumors, suggesting a favorable immunological response to 
therapy.63 64
In addition to the recruitment of TILs to lymphocyte- 
deficient sites, the goal of immunotherapy is to reverse 
the suppression of immune effector functions.65 Regu-
latory T cells (Tregs) and MDSCs can inhibit immune 
lymphoid function via local immune counter- regulatory 
pathways, leading to immunosuppression.66–68 Other 
immunosuppressive pathways, including the upregula-
tion of inhibitory CTLA- 4 and PD- 1 receptors on lympho-
cytes and direct tumor expression of inhibitory ligands, 
such as PD- L1, B7- H3, and B7x, can be used by tumors 
to limit T- cell responses.69 We found that intratumoral 
administration of ΔGRA17 increased the infiltration of 
CD8+ cytotoxic T cells, increased expression of IFN-γ and 
TNF-α while reversing immunosuppressive pathways and 
decreased the expression of Foxp3 in CD4+ T cells and 
PD- 1 in CD8+ T cells. It remains unknown what causes the 
relative reduction in Tregs, but parasite- relevant inflam-
matory cytokines have been shown to counter Tregs 
activity in Newcastle disease virus- injected tumors.70
As biotherapeutics, OVs and tumor- targeting bacteria 
can act at primary and metastatic tumor sites and this can 
be exploited when determining a locoregional or systemic 
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Figure 7 Local and abscopal effects of intratumoral Toxoplasma gondii ΔGRA17 plus programmed death ligand- 1 (PD- 
L1) blockade. (A) Schematic of treatment regimen and timeline for mice inoculated with B16- F10 cells. (B) Bioluminescence 
monitoring of B16- F10- Luc cells in live mice at days 10, 15, and 20. (C) Mice that achieved complete regression against 
B16- F10 for about 3 months after treatment with ΔGRA17 and/or PD- L1 blockade and age- matched treatment- naive mice were 
subcutaneously inoculated with B16- F10 cells. Tumor growth for individual mice is shown (n=8 mice/group). (D) Survival of 
B16- F10 rechallenged mice which achieved complete regression of melanoma after treatment. (E) Mice that achieved complete 
regression against B16- F10 rechallenge after treatment with ΔGRA17 in local and abscopal tumor models. The survival of 
tumor- bearing mice (n=8 mice/group) was presented as Kaplan- Meier plots and tested for significance using log- rank tests. 
Student’s t- test, ***p<0.001 compared with the indicated control.
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delivery strategy.16 17 In our study, we found that local injec-
tion of ΔGRA17 regressed tumors, including non- injected 
distant tumors. This regression was associated with increased 
infiltration of immune cells, upregulated immune- related 
pathways and enhanced innate and adaptive immune 
responses (eg, enhanced antigen processing, chemokines, 
T cell responses). Interestingly, the ΔGRA17 strain was not 
detected in non- injected distant tumors of WT C57BL/6 
mice. It is unclear whether ΔGRA17 tachyzoites have spread 
to the distant site, its draining lymph node, or another loca-
tion, or at a time point not assessed in the present study. 
These findings suggest that local injection of ΔGRA17 acti-
vated immune cells in the treated tumors, and these immune 
cells were subsequently recruited to distant tumors possibly 
via chemokines expressed in different tissue sites, which 
contributed to the clearance of the parasite in non- injected 
distant tumors. This mechanism underlies intratumoral 
oncolytic virotherapy, which can drive the activation of both 
antivirus and antitumor immunity. However, this vaccination 
strategy alone is of limited therapeutic value.16 17
The therapeutic efficacy against distant tumors was 
weak using ΔGRA17 monotherapy, although the signif-
icant increase of TILs in tumors, suggesting the immu-
nosuppressive nature of the tumor microenvironment.60 
In this study, we revealed the potential resistance mech-
anisms to ΔGRA17- induced immune activation. We 
detected that ΔGRA17 monotherapy up- regulated a few 
immune- inhibitory pathways, including PD- L1, in both 
injected tumors and distant tumors not injected by the 
parasite. This upregulation was most likely induced by 
intratumoral IFN-γ.71 72 Although PD- L1 generally down- 
regulates, or even dampens, T cell activity in tumor micro-
environment,73 74 recent clinical trials have shown that 
high tumor positivity for PD- L1 is common in patients 
who preferentially respond to PD- 1/PD- L1 and CTLA- 4 
blockade.3 5 75 76 Even though these immune- inhibitory 
mechanisms can reduce the efficacy of immunotherapy 
in the tumor microenvironment, the blockade of some 
of these mechanisms, using combination therapies, can 
lead to better therapeutic effects, for example, using local 
immunotherapies with OVs to prime ‘cold’ tumors for 
systemic ICB.16 17 In line with this assertion, our findings 
showed that a combination of intratumoral ΔGRA17 and 
systemic anti–PD- L1 antibodies led to the regression of 
distant B16- F10 tumors, together with improved mouse 
survival. The completely cured mice were also protected 
against tumor rechallenge, suggesting an establishment 
of a persistent immunity, although we did not deter-
mine whether memory lymphocytes resided in the bone 
marrow or the lymphoid organs.77 Infiltrated T lympho-
cytes with potent antitumor memory in the tumor micro-
environment are known to correlate with a more favorable 
outcome and better survival in clinical immunotherapy 
studies.78–80 Further clinical studies are needed to reveal 
specific immune cells responsible for the persistent anti-
tumor immunity observed in the present study. We also 
detected therapeutic efficacy in MC38 and LLC tumor 
models, which have previously exhibited poor sensitivity 
to immunotherapy. These results highlight that intratu-
moral inoculation with ΔGRA17 turned ‘cold’ tumors into 
‘hot’ tumors and primed the tumors to PD- L1 inhibition 
in tumor models that were unresponsive to such treat-
ment strategy. These results further support the concept 
that activation of immune responses and prevention of 
immuno- suppressive responses are needed for an effec-
tive antitumor therapeutic outcome.55
We detected an increase in immune cell infiltrates and 
regression of distant tumors together with better survival, 
Figure 8 Antitumor activity of Toxoplasma gondii ΔGRA17 and programmed death ligand- 1 (PD- L1) blockade therapy depends 
on CD8+ and natural killer (NK) cells. (A) Schematic showing the experimental protocol, including timeline for inoculation of 
B16- F10 cells, treatment with phosphate buffered saline (PBS) or ΔGRA17, and depletion of CD4+, CD8+, and NK cells using 
monoclonal antibodies. (B) Survival plot of mice that received the depleting antibodies before tumor implantation. (C) Survival 
plot of mice that received the depleting antibodies on day 0 of therapy. The survival of tumor- bearing mice (n=8 mice/group) 
was presented as Kaplan- Meier plots and tested for significance using log- rank tests. Student’s t- test, ***p<0.001, n/s, not 
significant compared with the indicated control.
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without evidence of disease recurrence in the lungs. B16- F10 
melanomas have the propensity for spontaneous metastases 
in the lungs, which can be mitigated by intratumoral onco-
lytic virotherapy.81 It is interesting to determine whether a 
similar effect exists in animal models with pre- established 
metastases. The present study demonstrated that inflamma-
tory responses and PD- L1 upregulation in tumors treated 
with ΔGRA17 can sensitize these tumors to PD- L1 inhibition; 
however, we did not monitor the inflammatory response in 
tumors. In one clinical trial, intratumoral administration 
of an oncolytic herpes virus, HSV1716, induced transient 
increases of fluorodeoxyglucose- positron emission tomog-
raphy activity in some patients, which is consistent with a 
tumor inflammatory reaction.82 A recent study demon-
strated that in vivo monitoring of tumor infiltration by CD8+ 
T cells could predict the therapeutic efficacy of anti- CTLA- 4 
therapy using a Zr- labeled anti- CD8 antibody fragment in 
animal models.83 These studies support in vivo monitoring 
of tumor infiltration, possibly by imaging CD8+ lymphocytes. 
Our study primarily focused on characterizing the adaptive 
immune response; however, it is important to determine the 
role of monocytes and NK cells, which are also upregulated 
in distant tumors in ΔGRA17- injected mice. Our findings 
showed that NK cells may contribute to early regression of 
tumor, but CD8+ T cells are required for long- term tumor 
control, suggesting that further experiments are warranted 
to clarify and confirm this observation.
Intratumoral administration of reovirus, in combina-
tion with systemic PD- 1 blockade, led to a synergistic tumor 
growth regression, which was dependent on NK and CD8+ T 
cells.84 In contrast to intratumoral injection of ΔGRA17, no 
significant PD- L1 upregulation was observed in response to 
administration of reovirus alone, with an increased expres-
sion of PD- L1 being ascribed to the tumor- infiltrating NK 
cells. Therapeutic efficacy of oncolytic herpes simplex virus 
expressing IL- 12, in combination with PD- 1 inhibition, in a 
glioma model is dependent on CD4+ T cells, CD8+ T cells, 
and macrophages.85 86 Notably, the combination of vesic-
ular stomatitis virus and adoptive cell therapy expended the 
PD- 1+CD8+ T cells, but an addition of anti- PD- 1 antibody 
failed to improve their therapeutic efficacy.87 88 The differ-
ences between these studies may probably be attributed to 
intrinsic differences between the different organisms and 
indicate that results with one pathogen should not be extrap-
olated to all pathogens.
A previous study showed that deletion of GRA17 in T. gondii 
type II ME49 strain resulted in a partial loss of the para-
site virulence where immunocompetent mice challenged 
intraperitoneally with ME49 ΔGRA17 survived infection 
doses up to 1×105 parasites, but a dose of 1×106 tachyzoites 
caused a 100% death rate.89 The ΔGRA17 strain is a repli-
cating, partially attenuated strain, as shown in the present 
and previous study.41 This raises safety concerns regarding 
the virulence of ΔGRA17 strain in any immuno- therapeutic 
intervention particularly immunocompromised hosts like 
patients with cancer. ΔGRA17 tachyzoites were detected in 
the distant tumors of NOD/SCID/IL- 2R g- chain knockout 
mice, showing that systematic dissemination of tachyzoites 
can occur from the inoculated tumors to a contralateral site 
in immunodeficient mice. Given the virulence of ΔGRA17 
strain at moderate infection doses and its tolerance to pyri-
methamine, the frontline therapeutic agent currently used 
to treat T. gondii infection in humans, and the inability of 
immunocompromised hosts to clear a replicating strain, the 
use of ΔGRA17 should be only limited to biological discovery. 
In the present study, ΔGRA17 strain was used as a model to 
test whether parasite therapy can make unresponsive mela-
noma tumors responsive to immunotherapy with anti- PD- 1 
blockade.
In summary, we have shown that intratumoral adminis-
tration of T. gondii RH ΔGRA17 tachyzoites induces systemic 
inflammatory responses in injected and non- injected distant 
tumors. We have also shown that localized ΔGRA17 therapy 
was able to sensitize poorly immunogenic tumors to ICB treat-
ment. Combined treatment with ΔGRA17 tachyzoites and 
anti- PD- L1 therapy significantly extended the survival of mice 
and suppressed tumor growth in preclinical mouse models 
of melanoma, Lewis lung carcinoma, and colon adenocarci-
noma. Attenuation of the tumor growth was detected in the 
injected and distant melanoma tumors, which was associated 
with upregulation of innate and adaptive immune pathways. 
Complete regression of tumors was underpinned by late 
IFN-γ-producing CD8+ cytotoxic T cells. The lack of inter-
ference of immunity to T. gondii with the antitumor immu-
nogenic effect of ΔGRA17 is an added advantage over the 
approach using OVs. Our data showed that T. gondii- induced 
immunotherapy improves the responsiveness of melanoma 
tumors to immunotherapy with PD- L1 blockade, as shown by 
the better treatment outcome compared with monotherapy. 
T. gondii ΔGRA17 should be used in further studies to iden-
tify the correlates of protection and reveal the molecular and 
immunological mechanisms needed to augment the efficacy 
of anti- PD- L1 therapy.
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Table S1 Primer sequences. 
Gene Sequence (5′→3′) 
B1 Sense: 5’- GGAACTGCATCCGTTCATGAG -3’ 
Anti-sense: 5’- TCTTTAAAGCGTTCGTGGTC -3’ 
H2-K1 Sense: 5’- CCGCGGACGCTGGATATAAA -3’ 
Anti-sense: 5’- AAATACCTCAGCGAGTGTGGG -3’ 
CD74 Sense: 5’- CCTTGCTGATGCGTCCAATG -3’ 
Anti-sense: 5’- CTGGGTCATGTTGCCGTACT-3’ 
H2-Eb1 Sense: 5’ –TGTCACGGTCGAGTGGAAAG -3’ 
Anti-sense: 5’- AAGTAGATGAACAGCCCCGC -3’ 
H2-T23 Sense: 5’- AGTATTGGGAGCGGGAGACT -3’ 
Anti-sense: 5’- AGCGTGTGAGATTCGTCGTT -3’ 
H2-Aa Sense: 5’- TTGTTCTGGCGAGTTTGGTT -3’ 
Anti-sense: 5’- AAGCTGCTCTCCTGAGTCTTC-3’ 
Psmb8 Sense: 5’- ACTACAGTTTCTCCGCGCAA -3’ 
Anti-sense: 5’- AAAGGACCTCAGGAATGCGG -3’ 
CCL3 Sense: 5’- GCCATATGGAGCTGACACCC -3’ 
Anti-sense: 5’- TCAACGATGAATTGGCGTGG -3’ 
IL-1b Sense: 5’- CTTTCCCGTGGACCTTCCAG -3’ 
Anti-sense: 5’- AATGGGAACGTCACACACCA -3’ 
CD80 Sense: 5’- CTTTCAGACCGGGGCACATA -3’ 
Anti-sense: 5’- AAGTCCTCTGACACGTGAGC -3’ 
Fas Sense: 5’- AACAGGCTGCATTGTTTGGG -3’ 
Anti-sense: 5’- TTCCTTTCCTGGATGGGGTTG -3’ 
IL2RA Sense: 5’- AACACCACCGATTTCTGGCT -3’ 
Anti-sense: 5’- GCAGGAAGTCTCACTCTCGG -3’ 
JAK3 Sense: 5’- TCTGATCCCTCAGCGCTCTT -3’ 
Anti-sense: 5’- TAAACAGGCAGGATGCCACA -3’ 
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